Ziad2022-11-25T14:06:05-05:00When you think of medical innovation, you may think of San Diego, Boston or the San Francisco Bay area. But entrepreneurial activity in medical innovation has been flourishing across Michigan and top talent, investors and leading life science corporations across the world have taken notice.
Fred Molnar is vice president of entrepreneurship and innovation at the Michigan Economic Development Corp.
For instance, this year an Ann Arbor-based biotech startup, RetroSense Therapeutics, was acquired by leading global pharmaceutical company Allergan plc for $60...
Ziad2022-11-25T14:06:06-05:00Millendo Therapeutics, Fontinalis Partners and RetroSense Therapeutics were the top honorees Wednesday at the Michigan Venture Capital Association's 2016 Awards Dinner at the Rattlesnake Club in Detroit. Read more >>
Ziad2022-11-25T14:06:06-05:00When Actavis Plc. acquired Allergan Inc. in March 2015, the company changed its name from Actavis Plc. to Allergan Plc (AGN)...In September 2016, Allergan announced the acquisition of Retrosense Therapeutics, a gene therapy company, in order to strengthen its Eye Care pipeline by Retrosense’s first-in-class technology RST-001 for the potential treatment of retinitis pigmentosa. Read more >>
Ziad2022-11-25T14:06:07-05:00Sean Ainsworth, the CEO of Ann Arbor-based RetroSense Therapeutics LLC, will be honored as entrepreneur of the year Thursday night at TechTown Detroit's annual Toast of the Town awards program. Read more >>
Ziad2022-11-25T14:06:07-05:00llergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead development...
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.